Disease · HP_0001618
Dysphonia
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Dysphonia. Diseases, record HP_0001618. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0001618
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Dysphonia
- Open Targets ID
- HP_0001618
- Other names
- Inability to produce voice sounds, Voice change
- Highest stage of its drugs
- Phase 3, for 3 of its 6 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs6
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DEXAMETHASONE | CHEMBL384467 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| HUMAN IMMUNOGLOBULIN G | CHEMBL1201599 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| KETOROLAC | CHEMBL469 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| KETAMINE | CHEMBL742 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MAGNESIUM SULFATE | CHEMBL3989857 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SUGAMMADEX | CHEMBL2111107 | Oligosaccharide | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets10
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| GRIN1 | Glutamate [NMDA] receptor | 1 | Glutamate [NMDA] receptor negative allosteric modulator | Unknown | https://conductscience.org/library/genes/2902 | Drugs and targets |
| GRIN2A | Glutamate [NMDA] receptor | 1 | Glutamate [NMDA] receptor negative allosteric modulator | Unknown | https://conductscience.org/library/genes/2903 | Drugs and targets |
| GRIN2B | Glutamate [NMDA] receptor | 1 | Glutamate [NMDA] receptor negative allosteric modulator | Unknown | https://conductscience.org/library/genes/2904 | Drugs and targets |
| GRIN2C | Glutamate [NMDA] receptor | 1 | Glutamate [NMDA] receptor negative allosteric modulator | Unknown | https://conductscience.org/library/genes/2905 | Drugs and targets |
| GRIN2D | Glutamate [NMDA] receptor | 1 | Glutamate [NMDA] receptor negative allosteric modulator | Unknown | https://conductscience.org/library/genes/2906 | Drugs and targets |
| GRIN3A | Glutamate [NMDA] receptor | 1 | Glutamate [NMDA] receptor negative allosteric modulator | Unknown | https://conductscience.org/library/genes/116443 | Drugs and targets |
| GRIN3B | Glutamate [NMDA] receptor | 1 | Glutamate [NMDA] receptor negative allosteric modulator | Unknown | https://conductscience.org/library/genes/116444 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 1 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| PTGS1 | Cyclooxygenase | 1 | Cyclooxygenase inhibitor | Phase 3 | https://conductscience.org/library/genes/5742 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 1 | Cyclooxygenase inhibitor | Phase 3 | https://conductscience.org/library/genes/5743 | Drugs and targets |
Trials4
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02728752 | Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy) | Phase 3 | 95 | 2021-04-21 | Dermatomyositis | HUMAN IMMUNOGLOBULIN G | Its record names the disease | ClinicalTrials.gov |
| NCT04650893 | The Effect of IV NSAID's and Corticosteroids on Dysphasia and Dysphonia Following ASDF | Phase 3 | 33 | 2024-08-23 | Dysphagia, Dysphonia | DEXAMETHASONE, KETOROLAC | Its record names the disease | ClinicalTrials.gov |
| NCT04161508 | Enhanced Recovery After Surgery for Anterior Cervcial Spine Surgeries in Elderly Patients | Not applicable | 100 | Other Fusion of Spine, Cervical Region | SUGAMMADEX | Its record names the disease | ClinicalTrials.gov | |
| NCT04705948 | Comparing the Effect of Ketamine and Magnesium Sulfate Gargling With Placebo on Post-operative Sore Throat | Not applicable | 60 | Postoperative Complications | KETAMINE, MAGNESIUM SULFATE | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials3
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Overall Period Octagam vs First Period Placebo: deaths from any cause | 0 of 95 | 0 of 48 | 143 | NCT02728752 | Trial comparisons |
| Overall Period Octagam vs First Period Placebo: serious adverse events | 14 of 95 | 2 of 48 | 143 | NCT02728752 | Trial comparisons |
| Octagam10% vs Placebo: Measure the Number of Patients Who Had an Increase of ≥20 Points on the Total Improvement Score (TIS) | 37 of 47 | 21 of 48 | 95 | NCT02728752 | Trial comparisons |
Papers from its trials6
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0001618
GET https://conductscience.org/api/diseases/v1/HP_0001618/drugs